Fasting vs. Stimulated C-Peptide Levels as Markers for Coronary Artery Disease in Type 2 Diabetes

Stimulated C-peptide levels are more effective than fasting C-peptide levels at identifying coronary artery disease (CAD) in patients with type 2 diabetes mellitus, according to a cross-sectional study published in Cureus. The research indicates that measuring C-peptide after glucose stimulation provides a more accurate discriminatory marker for cardiovascular risk in this patient population.

C-peptide is a byproduct created when the pancreas produces insulin. Because it is secreted in equal amounts to insulin but has a longer half-life and avoids the first-pass metabolism of the liver, clinicians use it to assess how much insulin a patient’s body is actually producing. In patients with type 2 diabetes, the decline of this insulin secretion often correlates with the progression of the disease and associated comorbidities.

C-Peptide Levels as Indicators of Coronary Artery Disease

The study focused on the ability of C-peptide to serve as a biomarker for CAD, a condition where the coronary arteries become narrowed or blocked. The researchers compared two different methods of measurement: fasting levels and stimulated levels.

Fasting C-peptide measures the hormone levels in the blood after a period of no food intake. Stimulated C-peptide measures the response after a glucose challenge, which forces the pancreas to secrete insulin and its corresponding C-peptide.

According to the Cureus report, stimulated C-peptide levels showed a higher sensitivity and specificity in discriminating between patients with and without CAD compared to fasting levels. This suggests that the pancreas’s ability to respond to a stimulus is a more critical indicator of vascular health than its baseline output.

Clinical Implications for Type 2 Diabetes Management

Type 2 diabetes significantly increases the risk of cardiovascular events. The study suggests that identifying patients with lower stimulated C-peptide levels may help clinicians pinpoint those at higher risk for CAD, potentially allowing for earlier intervention.

The findings highlight a specific physiological link: as beta-cell function declines in type 2 diabetes, the resulting insulin deficiency may contribute to an environment that accelerates atherosclerotic processes. By using the stimulated test, doctors can better gauge the actual reserve of the beta-cells.

Study Limitations and Context

As a cross-sectional study, these findings provide a snapshot of a specific group at a single point in time. This design allows researchers to find associations between C-peptide levels and the presence of CAD, but it does not establish a direct cause-and-effect relationship.

The researchers noted that while stimulated C-peptide is a superior marker, it requires more time and resources to administer than a simple fasting blood draw. Clinical adoption would depend on whether the increased diagnostic accuracy justifies the additional testing steps in a standard care setting.

Further longitudinal research is required to determine if monitoring changes in stimulated C-peptide over time can predict the onset of CAD before it is detectable via traditional imaging or stress tests.